Related Experiment Video
Updated: Mar 26, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.7K
Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation
Philipp Bushoven1, Sven Linzbach1, Mate Vamos1
1Department of Cardiology, Division of Clinical Electrophysiology, JW Goethe University, Frankfurt, Germany.
Arrhythmia & Electrophysiology Review
|February 3, 2016
Summary
Direct oral anticoagulants are now preferred over vitamin K antagonists for preventing stroke during cardioversion in atrial fibrillation patients. These newer agents offer improved handling, efficacy, and safety for restoring normal heart rhythm.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardioversion aims to restore sinus rhythm in symptomatic atrial fibrillation patients.
- Cardioversion carries a 1-3% risk of thromboembolism.
- Vitamin K antagonists have been the standard for thromboembolism prevention around cardioversion, despite limited trial data.
Purpose of the Study:
- To evaluate the role of direct oral anticoagulants (DOACs) in stroke prevention during cardioversion for atrial fibrillation.
- To compare the efficacy and safety of DOACs versus vitamin K antagonists in this clinical setting.
Main Methods:
- Review of existing data on the use of three approved DOACs during electrical or pharmacological cardioversion.
- Comparison of DOACs with vitamin K antagonists regarding stroke prevention and bleeding complications.
Main Results:
- DOACs have demonstrated usefulness during cardioversion.
- DOACs show favorable efficacy in stroke prevention.
- DOACs exhibit improved safety profiles concerning bleeding complications compared to vitamin K antagonists.
Conclusions:
- Direct oral anticoagulants are recommended as the preferred therapy over vitamin K antagonists for stroke prevention in non-valvular atrial fibrillation patients undergoing elective cardioversion.
- DOACs offer advantages in handling, efficacy, and safety, making them the preferred choice for cardioversion management.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
460
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
460
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
907
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
907
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
01:25Dysrhythmias VI: Management of Dysrhythmias
612
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
612
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
1.3K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.3K